Compliance Statement
This activity is an independent educational activity under the direction of CME LLC. The activity was planned and implemented in accordance with the Essential Areas and policies of the ACCME, the Ethical Opinions/Guidelines of the AMA, the FDA, the OIG, and the PhRMA Code on Interactions with Healthcare Professionals, thus assuring the highest degree of independence, fair balance, scientific rigor, and objectivity.
Accreditation Statements
CME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Provider approved by the California Board of Registered Nursing, Provider Number CEP12748 for 1.25 contact hours.
CME LLC is approved by the American Psychological Association to sponsor continuing education for psychologists. CME LLC maintains responsibility for this program and its content.
Credit Designation
CME LLC designates this enduring material for a maximum of 1.25
AMA PRA Category 1 Credits™. Physicians should only
claim the credit commensurate with the extent of their participation
in the activity.
Physician assistants, nurse practitioners, and nurses may
participate in this educational activity and earn a certificate of
completion, as AAPA, AANP, and ANCC accept AMA PRA Category 1
Credits™ through their reciprocity agreements.
Disclosures
Glenn J. Treisman, MD, has no financial relationships to disclose relating to the subject matter of this presentation.
Michael R. Clark, MD, MPH, MBA, serves as an advisor and consultant for Eli Lilly and Company.
Adam I. Kaplin, MD, PhD, has no financial relationships to disclose relating to the subject matter of this presentation.
Applicable CME LLC and DKBmed staff have no relationships to disclose relating to the subject matter of this activity.
This activity has been independently reviewed for balance.
Disclaimer
The opinions and recommendations expressed by faculty and
other experts whose input is included in this activity are
their own and do not necessarily reflect the views of the
sponsor. Discussions concerning drugs, dosages, and procedures
may reflect the clinical experience of the faculty or may be
derived from the professional literature or other sources and
may suggest uses that are investigational in nature and not
approved labeling or indications. Activity participants are
encouraged to refer to primary references or full prescribing
information resources.
Method of Participation
This enduring activity is a spin-off of a live presentation at the 2011 Psych Congress, November 7-10, 2011, in Las Vegas, NV. If you have earned a certificate for the live session, you are ineligible to earn a certificate for the enduring spin-off.
Participants are required to complete the activity, post-test and evaluation to earn a certificate of completion. A passing score of 80% or better is required. Participants are allowed 2 attempts to successfully complete the activity.
Estimated Time to Complete
The activity in its entirety should take approximately 70 minutes to complete.
Program Chair
Glenn J. Treisman, MD
Professor
Department of Psychiatry and Behavioral Sciences
Director, AIDS Psychiatry Service
The Johns Hopkins University School of Medicine
Baltimore, MD
Faculty
Michael R. Clark, MD, MPH, MBA
Associate Professor
Director, Pain Treatment Program
The Johns Hopkins University School of Medicine
Baltimore, MD
Adam I. Kaplin, MD, PhD
Assistant Professor of Psychiatry and Neurology
Chief Psychiatric Consultant
Johns Hopkins Multiple Sclerosis and Transverse Myelitis Centers
The Johns Hopkins University School of Medicine
Baltimore, MD
Goal Statement
The goal of this activity is to provide mental health care professionals with education on the
importance of remission, measurement-based approaches to care, and application of guidelines to treat major depression and ultimately achieve remission.
Learning Objectives
After completing this activity, participants should be able to:
- Describe the impact of residual symptoms and the need to achieve complete remission when treating patients with major depression
- Identify evidence-based approaches to advancing therapy to promote remission, including optimizing initial therapy and employing switching-and-augmenting strategies
- Discuss the latest evidence describing measurement-based approaches to care in major depression and integrating these tools into clinical practice
- Apply the 2010 APA guidelines for treating major depression, focusing on treatment goals, measurement-based tools, and methods to achieve remission
Target Audience
This continuing medical education activity is intended for psychiatrists and other healthcare professionals who seek to improve their care for patients with MDD and the outcomes resulting from that care.
Sponsored By
Supporter Statement
This activity is supported by an educational grant from Bristol-Myers Squibb.
Developed in partnership with:
